Skip to content
Try Mental Wellness – Lifestyle
Author:
Cyllene Therapeutics
Cyllene Therapeutics Presents Interim Data from Phase 1b/2a Clinical Trial Showing EG110A Reduced Urinary Episodes in Patients with Spinal Cord Injury at the International Continence Society (ICS) Conference
October 7, 2026
Cyllene Therapeutics Appoints Seasoned Biotech Executive Dr Marc Grasso as Chief Financial Officer
September 17, 2026
Cyllene Therapeutics Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EG110A in Neurogenic Detrusor Overactivity (NDO)
September 14, 2026
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
July 23, 2026
Cyllene Therapeutics (formerly known as EG 427) Raises €33 Million Series C Financing to Advance Clinical Development of EG110A and Pipeline Expansion
July 7, 2026